Immunitor Reports Positive Data for Liver Cancer Immunotherapy

Immunitor, a Vancouver immuno-oncology company with offices in Mongolia and Hong Kong, reported positive data from a Phase II trial of its oral vaccine in liver cancer patients. Over 90% of patients with advanced liver cancer were alive after a median 12 months, while only 10% of patients who received Nexavar (sorafenib) reached that mark. The trial enrolled 75 patients with late-stage hepatocellular carcinoma. Immunitor has started a randomized, double-blind, placebo-controlled Phase III trial of the vaccine, Hepko-V5, at the Mongolian National Cancer Center. More details.... Share this with colleagues: // //